nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—melanoma	0.238	1	CbGaD
Nefazodone—CYP3A4—Temozolomide—melanoma	0.0736	0.189	CbGbCtD
Nefazodone—CYP2D6—Vemurafenib—melanoma	0.0634	0.163	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0473	0.122	CbGbCtD
Nefazodone—CYP3A7—Docetaxel—melanoma	0.0473	0.122	CbGbCtD
Nefazodone—ABCB1—Dactinomycin—melanoma	0.0447	0.115	CbGbCtD
Nefazodone—CYP3A4—Vemurafenib—melanoma	0.0403	0.104	CbGbCtD
Nefazodone—CYP3A5—Docetaxel—melanoma	0.0355	0.0912	CbGbCtD
Nefazodone—ABCB1—Docetaxel—melanoma	0.0231	0.0594	CbGbCtD
Nefazodone—CYP3A4—Docetaxel—melanoma	0.0138	0.0356	CbGbCtD
Nefazodone—Dermatitis bullous—Docetaxel—melanoma	0.00055	0.00238	CcSEcCtD
Nefazodone—Haemoglobin—Temozolomide—melanoma	0.00055	0.00238	CcSEcCtD
Nefazodone—Hepatitis—Temozolomide—melanoma	0.000547	0.00236	CcSEcCtD
Nefazodone—Haemorrhage—Temozolomide—melanoma	0.000547	0.00236	CcSEcCtD
Nefazodone—Asthenia—Vemurafenib—melanoma	0.000546	0.00236	CcSEcCtD
Nefazodone—Visual impairment—Carmustine—melanoma	0.000546	0.00236	CcSEcCtD
Nefazodone—Hallucination—Temozolomide—melanoma	0.000544	0.00235	CcSEcCtD
Nefazodone—Hypoaesthesia—Temozolomide—melanoma	0.000544	0.00235	CcSEcCtD
Nefazodone—Pharyngitis—Temozolomide—melanoma	0.000543	0.00235	CcSEcCtD
Nefazodone—Chills—Dactinomycin—melanoma	0.000543	0.00235	CcSEcCtD
Nefazodone—Oedema peripheral—Temozolomide—melanoma	0.000539	0.00233	CcSEcCtD
Nefazodone—Pruritus—Vemurafenib—melanoma	0.000538	0.00233	CcSEcCtD
Nefazodone—Alopecia—Dactinomycin—melanoma	0.000535	0.00231	CcSEcCtD
Nefazodone—Hyponatraemia—Docetaxel—melanoma	0.000528	0.00228	CcSEcCtD
Nefazodone—Visual impairment—Temozolomide—melanoma	0.000527	0.00228	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000526	0.00227	CcSEcCtD
Nefazodone—Flushing—Carmustine—melanoma	0.000525	0.00227	CcSEcCtD
Nefazodone—Ill-defined disorder—Bleomycin—melanoma	0.000524	0.00226	CcSEcCtD
Nefazodone—Anaemia—Bleomycin—melanoma	0.000522	0.00226	CcSEcCtD
Nefazodone—Diarrhoea—Vemurafenib—melanoma	0.00052	0.00225	CcSEcCtD
Nefazodone—Migraine—Docetaxel—melanoma	0.000518	0.00224	CcSEcCtD
Nefazodone—Erythema multiforme—Temozolomide—melanoma	0.000517	0.00224	CcSEcCtD
Nefazodone—Tinnitus—Temozolomide—melanoma	0.00051	0.0022	CcSEcCtD
Nefazodone—Malaise—Bleomycin—melanoma	0.000509	0.0022	CcSEcCtD
Nefazodone—Flushing—Temozolomide—melanoma	0.000508	0.00219	CcSEcCtD
Nefazodone—Leukopenia—Bleomycin—melanoma	0.000505	0.00218	CcSEcCtD
Nefazodone—Dizziness—Vemurafenib—melanoma	0.000503	0.00217	CcSEcCtD
Nefazodone—Alopecia—Carmustine—melanoma	0.0005	0.00216	CcSEcCtD
Nefazodone—Ataxia—Docetaxel—melanoma	0.000495	0.00214	CcSEcCtD
Nefazodone—Cough—Bleomycin—melanoma	0.000493	0.00213	CcSEcCtD
Nefazodone—Chills—Temozolomide—melanoma	0.000491	0.00212	CcSEcCtD
Nefazodone—Dehydration—Docetaxel—melanoma	0.000489	0.00211	CcSEcCtD
Nefazodone—Ill-defined disorder—Dactinomycin—melanoma	0.000489	0.00211	CcSEcCtD
Nefazodone—Anaemia—Dactinomycin—melanoma	0.000487	0.0021	CcSEcCtD
Nefazodone—Liver function test abnormal—Docetaxel—melanoma	0.000486	0.0021	CcSEcCtD
Nefazodone—Vomiting—Vemurafenib—melanoma	0.000484	0.00209	CcSEcCtD
Nefazodone—Alopecia—Temozolomide—melanoma	0.000483	0.00209	CcSEcCtD
Nefazodone—Dry skin—Docetaxel—melanoma	0.000482	0.00208	CcSEcCtD
Nefazodone—Chest pain—Bleomycin—melanoma	0.000481	0.00208	CcSEcCtD
Nefazodone—Myalgia—Bleomycin—melanoma	0.000481	0.00208	CcSEcCtD
Nefazodone—Orthostatic hypotension—Docetaxel—melanoma	0.00048	0.00208	CcSEcCtD
Nefazodone—Rash—Vemurafenib—melanoma	0.00048	0.00207	CcSEcCtD
Nefazodone—Dermatitis—Vemurafenib—melanoma	0.000479	0.00207	CcSEcCtD
Nefazodone—Back pain—Carmustine—melanoma	0.000477	0.00206	CcSEcCtD
Nefazodone—Headache—Vemurafenib—melanoma	0.000476	0.00206	CcSEcCtD
Nefazodone—Discomfort—Bleomycin—melanoma	0.000475	0.00205	CcSEcCtD
Nefazodone—Malaise—Dactinomycin—melanoma	0.000475	0.00205	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000474	0.00205	CcSEcCtD
Nefazodone—Cramp muscle—Docetaxel—melanoma	0.000474	0.00205	CcSEcCtD
Nefazodone—Leukopenia—Dactinomycin—melanoma	0.000471	0.00204	CcSEcCtD
Nefazodone—Dysgeusia—Temozolomide—melanoma	0.000466	0.00202	CcSEcCtD
Nefazodone—Confusional state—Bleomycin—melanoma	0.000465	0.00201	CcSEcCtD
Nefazodone—Vision blurred—Carmustine—melanoma	0.000464	0.00201	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Docetaxel—melanoma	0.000464	0.002	CcSEcCtD
Nefazodone—Tremor—Carmustine—melanoma	0.000462	0.002	CcSEcCtD
Nefazodone—Anaphylactic shock—Bleomycin—melanoma	0.000461	0.00199	CcSEcCtD
Nefazodone—Oedema—Bleomycin—melanoma	0.000461	0.00199	CcSEcCtD
Nefazodone—Back pain—Temozolomide—melanoma	0.000461	0.00199	CcSEcCtD
Nefazodone—Infection—Bleomycin—melanoma	0.000458	0.00198	CcSEcCtD
Nefazodone—Anaemia—Carmustine—melanoma	0.000456	0.00197	CcSEcCtD
Nefazodone—Dysphagia—Docetaxel—melanoma	0.000455	0.00196	CcSEcCtD
Nefazodone—Agitation—Carmustine—melanoma	0.000453	0.00196	CcSEcCtD
Nefazodone—Nausea—Vemurafenib—melanoma	0.000452	0.00195	CcSEcCtD
Nefazodone—Thrombocytopenia—Bleomycin—melanoma	0.000451	0.00195	CcSEcCtD
Nefazodone—Vision blurred—Temozolomide—melanoma	0.000449	0.00194	CcSEcCtD
Nefazodone—Myalgia—Dactinomycin—melanoma	0.000448	0.00194	CcSEcCtD
Nefazodone—Tremor—Temozolomide—melanoma	0.000446	0.00193	CcSEcCtD
Nefazodone—Discomfort—Dactinomycin—melanoma	0.000443	0.00191	CcSEcCtD
Nefazodone—Angina pectoris—Docetaxel—melanoma	0.000443	0.00191	CcSEcCtD
Nefazodone—Ill-defined disorder—Temozolomide—melanoma	0.000442	0.00191	CcSEcCtD
Nefazodone—Leukopenia—Carmustine—melanoma	0.000441	0.00191	CcSEcCtD
Nefazodone—Anaemia—Temozolomide—melanoma	0.00044	0.0019	CcSEcCtD
Nefazodone—Anorexia—Bleomycin—melanoma	0.000439	0.0019	CcSEcCtD
Nefazodone—Agitation—Temozolomide—melanoma	0.000438	0.00189	CcSEcCtD
Nefazodone—Angioedema—Temozolomide—melanoma	0.000435	0.00188	CcSEcCtD
Nefazodone—Hypotension—Bleomycin—melanoma	0.000431	0.00186	CcSEcCtD
Nefazodone—Oedema—Dactinomycin—melanoma	0.00043	0.00186	CcSEcCtD
Nefazodone—Malaise—Temozolomide—melanoma	0.00043	0.00186	CcSEcCtD
Nefazodone—Vertigo—Temozolomide—melanoma	0.000428	0.00185	CcSEcCtD
Nefazodone—Convulsion—Carmustine—melanoma	0.000427	0.00185	CcSEcCtD
Nefazodone—Infection—Dactinomycin—melanoma	0.000427	0.00185	CcSEcCtD
Nefazodone—Leukopenia—Temozolomide—melanoma	0.000426	0.00184	CcSEcCtD
Nefazodone—Hypertension—Carmustine—melanoma	0.000426	0.00184	CcSEcCtD
Nefazodone—Palpitations—Temozolomide—melanoma	0.000421	0.00182	CcSEcCtD
Nefazodone—Thrombocytopenia—Dactinomycin—melanoma	0.000421	0.00182	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Bleomycin—melanoma	0.00042	0.00181	CcSEcCtD
Nefazodone—Myalgia—Carmustine—melanoma	0.00042	0.00181	CcSEcCtD
Nefazodone—Chest pain—Carmustine—melanoma	0.00042	0.00181	CcSEcCtD
Nefazodone—Anxiety—Carmustine—melanoma	0.000418	0.00181	CcSEcCtD
Nefazodone—Cough—Temozolomide—melanoma	0.000416	0.0018	CcSEcCtD
Nefazodone—Paraesthesia—Bleomycin—melanoma	0.000414	0.00179	CcSEcCtD
Nefazodone—Weight increased—Docetaxel—melanoma	0.000414	0.00179	CcSEcCtD
Nefazodone—Convulsion—Temozolomide—melanoma	0.000413	0.00178	CcSEcCtD
Nefazodone—Weight decreased—Docetaxel—melanoma	0.000411	0.00178	CcSEcCtD
Nefazodone—Hypertension—Temozolomide—melanoma	0.000411	0.00178	CcSEcCtD
Nefazodone—Dyspnoea—Bleomycin—melanoma	0.000411	0.00178	CcSEcCtD
Nefazodone—Anorexia—Dactinomycin—melanoma	0.00041	0.00177	CcSEcCtD
Nefazodone—Pneumonia—Docetaxel—melanoma	0.000408	0.00176	CcSEcCtD
Nefazodone—Confusional state—Carmustine—melanoma	0.000406	0.00175	CcSEcCtD
Nefazodone—Myalgia—Temozolomide—melanoma	0.000405	0.00175	CcSEcCtD
Nefazodone—Arthralgia—Temozolomide—melanoma	0.000405	0.00175	CcSEcCtD
Nefazodone—Anxiety—Temozolomide—melanoma	0.000404	0.00175	CcSEcCtD
Nefazodone—Oedema—Carmustine—melanoma	0.000402	0.00174	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000402	0.00174	CcSEcCtD
Nefazodone—Discomfort—Temozolomide—melanoma	0.000401	0.00173	CcSEcCtD
Nefazodone—Decreased appetite—Bleomycin—melanoma	0.000401	0.00173	CcSEcCtD
Nefazodone—Infection—Carmustine—melanoma	0.0004	0.00173	CcSEcCtD
Nefazodone—Dry mouth—Temozolomide—melanoma	0.000397	0.00171	CcSEcCtD
Nefazodone—Stomatitis—Docetaxel—melanoma	0.000395	0.00171	CcSEcCtD
Nefazodone—Pain—Bleomycin—melanoma	0.000394	0.0017	CcSEcCtD
Nefazodone—Conjunctivitis—Docetaxel—melanoma	0.000394	0.0017	CcSEcCtD
Nefazodone—Thrombocytopenia—Carmustine—melanoma	0.000394	0.0017	CcSEcCtD
Nefazodone—Tachycardia—Carmustine—melanoma	0.000393	0.0017	CcSEcCtD
Nefazodone—Confusional state—Temozolomide—melanoma	0.000392	0.00169	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000392	0.00169	CcSEcCtD
Nefazodone—Anaphylactic shock—Temozolomide—melanoma	0.000389	0.00168	CcSEcCtD
Nefazodone—Oedema—Temozolomide—melanoma	0.000389	0.00168	CcSEcCtD
Nefazodone—Infection—Temozolomide—melanoma	0.000386	0.00167	CcSEcCtD
Nefazodone—Anorexia—Carmustine—melanoma	0.000383	0.00166	CcSEcCtD
Nefazodone—Epistaxis—Docetaxel—melanoma	0.000382	0.00165	CcSEcCtD
Nefazodone—Thrombocytopenia—Temozolomide—melanoma	0.000381	0.00164	CcSEcCtD
Nefazodone—Feeling abnormal—Bleomycin—melanoma	0.00038	0.00164	CcSEcCtD
Nefazodone—Hypotension—Carmustine—melanoma	0.000376	0.00162	CcSEcCtD
Nefazodone—Hyperhidrosis—Temozolomide—melanoma	0.000376	0.00162	CcSEcCtD
Nefazodone—Decreased appetite—Dactinomycin—melanoma	0.000374	0.00161	CcSEcCtD
Nefazodone—Anorexia—Temozolomide—melanoma	0.000371	0.0016	CcSEcCtD
Nefazodone—Pain—Dactinomycin—melanoma	0.000368	0.00159	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Carmustine—melanoma	0.000366	0.00158	CcSEcCtD
Nefazodone—Urticaria—Bleomycin—melanoma	0.000366	0.00158	CcSEcCtD
Nefazodone—Haemoglobin—Docetaxel—melanoma	0.000366	0.00158	CcSEcCtD
Nefazodone—Rhinitis—Docetaxel—melanoma	0.000365	0.00158	CcSEcCtD
Nefazodone—Body temperature increased—Bleomycin—melanoma	0.000364	0.00157	CcSEcCtD
Nefazodone—Hepatitis—Docetaxel—melanoma	0.000364	0.00157	CcSEcCtD
Nefazodone—Haemorrhage—Docetaxel—melanoma	0.000364	0.00157	CcSEcCtD
Nefazodone—Insomnia—Carmustine—melanoma	0.000364	0.00157	CcSEcCtD
Nefazodone—Hypoaesthesia—Docetaxel—melanoma	0.000362	0.00156	CcSEcCtD
Nefazodone—Paraesthesia—Carmustine—melanoma	0.000361	0.00156	CcSEcCtD
Nefazodone—Pharyngitis—Docetaxel—melanoma	0.000361	0.00156	CcSEcCtD
Nefazodone—Dyspnoea—Carmustine—melanoma	0.000359	0.00155	CcSEcCtD
Nefazodone—Oedema peripheral—Docetaxel—melanoma	0.000358	0.00155	CcSEcCtD
Nefazodone—Somnolence—Carmustine—melanoma	0.000358	0.00155	CcSEcCtD
Nefazodone—Feeling abnormal—Dactinomycin—melanoma	0.000354	0.00153	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Temozolomide—melanoma	0.000354	0.00153	CcSEcCtD
Nefazodone—Insomnia—Temozolomide—melanoma	0.000352	0.00152	CcSEcCtD
Nefazodone—Gastrointestinal pain—Dactinomycin—melanoma	0.000351	0.00152	CcSEcCtD
Nefazodone—Visual impairment—Docetaxel—melanoma	0.000351	0.00152	CcSEcCtD
Nefazodone—Decreased appetite—Carmustine—melanoma	0.00035	0.00151	CcSEcCtD
Nefazodone—Paraesthesia—Temozolomide—melanoma	0.000349	0.00151	CcSEcCtD
Nefazodone—Dyspnoea—Temozolomide—melanoma	0.000347	0.0015	CcSEcCtD
Nefazodone—Somnolence—Temozolomide—melanoma	0.000346	0.00149	CcSEcCtD
Nefazodone—Erythema multiforme—Docetaxel—melanoma	0.000344	0.00149	CcSEcCtD
Nefazodone—Pain—Carmustine—melanoma	0.000344	0.00149	CcSEcCtD
Nefazodone—Constipation—Carmustine—melanoma	0.000344	0.00149	CcSEcCtD
Nefazodone—Dyspepsia—Temozolomide—melanoma	0.000342	0.00148	CcSEcCtD
Nefazodone—Abdominal pain—Dactinomycin—melanoma	0.00034	0.00147	CcSEcCtD
Nefazodone—Body temperature increased—Dactinomycin—melanoma	0.00034	0.00147	CcSEcCtD
Nefazodone—Hypersensitivity—Bleomycin—melanoma	0.00034	0.00147	CcSEcCtD
Nefazodone—Decreased appetite—Temozolomide—melanoma	0.000338	0.00146	CcSEcCtD
Nefazodone—Flushing—Docetaxel—melanoma	0.000338	0.00146	CcSEcCtD
Nefazodone—Pain—Temozolomide—melanoma	0.000332	0.00144	CcSEcCtD
Nefazodone—Constipation—Temozolomide—melanoma	0.000332	0.00144	CcSEcCtD
Nefazodone—Feeling abnormal—Carmustine—melanoma	0.000331	0.00143	CcSEcCtD
Nefazodone—Asthenia—Bleomycin—melanoma	0.000331	0.00143	CcSEcCtD
Nefazodone—Gastrointestinal pain—Carmustine—melanoma	0.000329	0.00142	CcSEcCtD
Nefazodone—Chills—Docetaxel—melanoma	0.000326	0.00141	CcSEcCtD
Nefazodone—Pruritus—Bleomycin—melanoma	0.000326	0.00141	CcSEcCtD
Nefazodone—Alopecia—Docetaxel—melanoma	0.000322	0.00139	CcSEcCtD
Nefazodone—Feeling abnormal—Temozolomide—melanoma	0.00032	0.00138	CcSEcCtD
Nefazodone—Abdominal pain—Carmustine—melanoma	0.000318	0.00137	CcSEcCtD
Nefazodone—Body temperature increased—Carmustine—melanoma	0.000318	0.00137	CcSEcCtD
Nefazodone—Gastrointestinal pain—Temozolomide—melanoma	0.000318	0.00137	CcSEcCtD
Nefazodone—Hypersensitivity—Dactinomycin—melanoma	0.000317	0.00137	CcSEcCtD
Nefazodone—Dysgeusia—Docetaxel—melanoma	0.00031	0.00134	CcSEcCtD
Nefazodone—Urticaria—Temozolomide—melanoma	0.000309	0.00133	CcSEcCtD
Nefazodone—Asthenia—Dactinomycin—melanoma	0.000308	0.00133	CcSEcCtD
Nefazodone—Abdominal pain—Temozolomide—melanoma	0.000307	0.00133	CcSEcCtD
Nefazodone—Body temperature increased—Temozolomide—melanoma	0.000307	0.00133	CcSEcCtD
Nefazodone—Back pain—Docetaxel—melanoma	0.000306	0.00132	CcSEcCtD
Nefazodone—Muscle spasms—Docetaxel—melanoma	0.000305	0.00132	CcSEcCtD
Nefazodone—Hypersensitivity—Carmustine—melanoma	0.000296	0.00128	CcSEcCtD
Nefazodone—Diarrhoea—Dactinomycin—melanoma	0.000294	0.00127	CcSEcCtD
Nefazodone—Vomiting—Bleomycin—melanoma	0.000293	0.00127	CcSEcCtD
Nefazodone—Anaemia—Docetaxel—melanoma	0.000293	0.00127	CcSEcCtD
Nefazodone—Rash—Bleomycin—melanoma	0.000291	0.00126	CcSEcCtD
Nefazodone—Dermatitis—Bleomycin—melanoma	0.00029	0.00125	CcSEcCtD
Nefazodone—Asthenia—Carmustine—melanoma	0.000289	0.00125	CcSEcCtD
Nefazodone—Hypersensitivity—Temozolomide—melanoma	0.000286	0.00124	CcSEcCtD
Nefazodone—Syncope—Docetaxel—melanoma	0.000284	0.00123	CcSEcCtD
Nefazodone—Leukopenia—Docetaxel—melanoma	0.000284	0.00123	CcSEcCtD
Nefazodone—Palpitations—Docetaxel—melanoma	0.00028	0.00121	CcSEcCtD
Nefazodone—Asthenia—Temozolomide—melanoma	0.000279	0.00121	CcSEcCtD
Nefazodone—Loss of consciousness—Docetaxel—melanoma	0.000278	0.0012	CcSEcCtD
Nefazodone—Cough—Docetaxel—melanoma	0.000276	0.00119	CcSEcCtD
Nefazodone—Diarrhoea—Carmustine—melanoma	0.000275	0.00119	CcSEcCtD
Nefazodone—Pruritus—Temozolomide—melanoma	0.000275	0.00119	CcSEcCtD
Nefazodone—Convulsion—Docetaxel—melanoma	0.000274	0.00119	CcSEcCtD
Nefazodone—Nausea—Bleomycin—melanoma	0.000274	0.00118	CcSEcCtD
Nefazodone—Hypertension—Docetaxel—melanoma	0.000273	0.00118	CcSEcCtD
Nefazodone—Vomiting—Dactinomycin—melanoma	0.000273	0.00118	CcSEcCtD
Nefazodone—Rash—Dactinomycin—melanoma	0.000271	0.00117	CcSEcCtD
Nefazodone—Chest pain—Docetaxel—melanoma	0.00027	0.00117	CcSEcCtD
Nefazodone—Myalgia—Docetaxel—melanoma	0.00027	0.00117	CcSEcCtD
Nefazodone—Arthralgia—Docetaxel—melanoma	0.00027	0.00117	CcSEcCtD
Nefazodone—Dizziness—Carmustine—melanoma	0.000266	0.00115	CcSEcCtD
Nefazodone—Diarrhoea—Temozolomide—melanoma	0.000266	0.00115	CcSEcCtD
Nefazodone—Dry mouth—Docetaxel—melanoma	0.000264	0.00114	CcSEcCtD
Nefazodone—Confusional state—Docetaxel—melanoma	0.000261	0.00113	CcSEcCtD
Nefazodone—Anaphylactic shock—Docetaxel—melanoma	0.000259	0.00112	CcSEcCtD
Nefazodone—Oedema—Docetaxel—melanoma	0.000259	0.00112	CcSEcCtD
Nefazodone—Dizziness—Temozolomide—melanoma	0.000257	0.00111	CcSEcCtD
Nefazodone—Infection—Docetaxel—melanoma	0.000257	0.00111	CcSEcCtD
Nefazodone—Vomiting—Carmustine—melanoma	0.000256	0.00111	CcSEcCtD
Nefazodone—Nausea—Dactinomycin—melanoma	0.000255	0.0011	CcSEcCtD
Nefazodone—Shock—Docetaxel—melanoma	0.000254	0.0011	CcSEcCtD
Nefazodone—Rash—Carmustine—melanoma	0.000254	0.0011	CcSEcCtD
Nefazodone—Dermatitis—Carmustine—melanoma	0.000253	0.0011	CcSEcCtD
Nefazodone—Thrombocytopenia—Docetaxel—melanoma	0.000253	0.00109	CcSEcCtD
Nefazodone—Tachycardia—Docetaxel—melanoma	0.000252	0.00109	CcSEcCtD
Nefazodone—Headache—Carmustine—melanoma	0.000252	0.00109	CcSEcCtD
Nefazodone—Vomiting—Temozolomide—melanoma	0.000247	0.00107	CcSEcCtD
Nefazodone—Anorexia—Docetaxel—melanoma	0.000246	0.00106	CcSEcCtD
Nefazodone—Rash—Temozolomide—melanoma	0.000245	0.00106	CcSEcCtD
Nefazodone—Dermatitis—Temozolomide—melanoma	0.000245	0.00106	CcSEcCtD
Nefazodone—Headache—Temozolomide—melanoma	0.000244	0.00105	CcSEcCtD
Nefazodone—Hypotension—Docetaxel—melanoma	0.000242	0.00104	CcSEcCtD
Nefazodone—Nausea—Carmustine—melanoma	0.000239	0.00103	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Docetaxel—melanoma	0.000236	0.00102	CcSEcCtD
Nefazodone—Insomnia—Docetaxel—melanoma	0.000234	0.00101	CcSEcCtD
Nefazodone—Paraesthesia—Docetaxel—melanoma	0.000232	0.001	CcSEcCtD
Nefazodone—Nausea—Temozolomide—melanoma	0.000231	0.000998	CcSEcCtD
Nefazodone—Dyspnoea—Docetaxel—melanoma	0.00023	0.000996	CcSEcCtD
Nefazodone—Somnolence—Docetaxel—melanoma	0.00023	0.000993	CcSEcCtD
Nefazodone—Dyspepsia—Docetaxel—melanoma	0.000228	0.000983	CcSEcCtD
Nefazodone—Decreased appetite—Docetaxel—melanoma	0.000225	0.000971	CcSEcCtD
Nefazodone—Pain—Docetaxel—melanoma	0.000221	0.000955	CcSEcCtD
Nefazodone—Constipation—Docetaxel—melanoma	0.000221	0.000955	CcSEcCtD
Nefazodone—Feeling abnormal—Docetaxel—melanoma	0.000213	0.000921	CcSEcCtD
Nefazodone—Gastrointestinal pain—Docetaxel—melanoma	0.000211	0.000914	CcSEcCtD
Nefazodone—Abdominal pain—Docetaxel—melanoma	0.000204	0.000883	CcSEcCtD
Nefazodone—Body temperature increased—Docetaxel—melanoma	0.000204	0.000883	CcSEcCtD
Nefazodone—Hypersensitivity—Docetaxel—melanoma	0.00019	0.000823	CcSEcCtD
Nefazodone—Asthenia—Docetaxel—melanoma	0.000185	0.000802	CcSEcCtD
Nefazodone—Pruritus—Docetaxel—melanoma	0.000183	0.00079	CcSEcCtD
Nefazodone—Diarrhoea—Docetaxel—melanoma	0.000177	0.000764	CcSEcCtD
Nefazodone—Dizziness—Docetaxel—melanoma	0.000171	0.000739	CcSEcCtD
Nefazodone—Vomiting—Docetaxel—melanoma	0.000164	0.00071	CcSEcCtD
Nefazodone—Rash—Docetaxel—melanoma	0.000163	0.000704	CcSEcCtD
Nefazodone—Dermatitis—Docetaxel—melanoma	0.000163	0.000704	CcSEcCtD
Nefazodone—Headache—Docetaxel—melanoma	0.000162	0.0007	CcSEcCtD
Nefazodone—Nausea—Docetaxel—melanoma	0.000154	0.000664	CcSEcCtD
Nefazodone—Domperidone—ABCB1—melanoma	3.81e-05	0.204	CrCbGaD
Nefazodone—Aripiprazole—ABCB1—melanoma	2.94e-05	0.157	CrCbGaD
Nefazodone—Trazodone—ABCB1—melanoma	2.93e-05	0.157	CrCbGaD
Nefazodone—Thioproperazine—ALB—melanoma	2.92e-05	0.156	CrCbGaD
Nefazodone—Fluphenazine—ABCB1—melanoma	2.37e-05	0.127	CrCbGaD
Nefazodone—Trifluoperazine—ABCB1—melanoma	1.9e-05	0.101	CrCbGaD
Nefazodone—Quetiapine—ABCB1—melanoma	1.84e-05	0.0983	CrCbGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CB—melanoma	7.66e-06	5.44e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAP2K1—melanoma	7.64e-06	5.43e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CB—melanoma	7.62e-06	5.41e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CD—melanoma	7.59e-06	5.39e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CD—melanoma	7.57e-06	5.38e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GNA11—melanoma	7.57e-06	5.37e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	7.53e-06	5.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK3—melanoma	7.52e-06	5.34e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PIK3CA—melanoma	7.52e-06	5.34e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MDM2—melanoma	7.5e-06	5.33e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAP2K1—melanoma	7.48e-06	5.32e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ALB—melanoma	7.47e-06	5.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CD—melanoma	7.43e-06	5.28e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—melanoma	7.43e-06	5.28e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—FASN—melanoma	7.4e-06	5.26e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—melanoma	7.39e-06	5.25e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BRAF—melanoma	7.38e-06	5.25e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	7.36e-06	5.23e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—melanoma	7.36e-06	5.23e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—melanoma	7.32e-06	5.2e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HRAS—melanoma	7.31e-06	5.19e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CB—melanoma	7.29e-06	5.18e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC5A5—melanoma	7.28e-06	5.17e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—melanoma	7.28e-06	5.17e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HRAS—melanoma	7.27e-06	5.17e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGF2—melanoma	7.27e-06	5.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CB—melanoma	7.2e-06	5.11e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—melanoma	7.19e-06	5.11e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1B—melanoma	7.19e-06	5.11e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK1—melanoma	7.16e-06	5.09e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—melanoma	7.16e-06	5.08e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1B—melanoma	7.15e-06	5.08e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—melanoma	7.13e-06	5.07e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGF2—melanoma	7.12e-06	5.06e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—melanoma	7.11e-06	5.05e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—melanoma	7.07e-06	5.02e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—melanoma	7.04e-06	5e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—melanoma	7.03e-06	5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GNAQ—melanoma	7.03e-06	5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CD44—melanoma	7.03e-06	5e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—melanoma	7.01e-06	4.98e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—melanoma	7.01e-06	4.98e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—melanoma	7e-06	4.97e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—melanoma	7e-06	4.97e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRAS—melanoma	6.96e-06	4.95e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—melanoma	6.96e-06	4.95e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAP2K1—melanoma	6.95e-06	4.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CD—melanoma	6.91e-06	4.91e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—melanoma	6.86e-06	4.87e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1B—melanoma	6.84e-06	4.86e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	6.84e-06	4.86e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—melanoma	6.83e-06	4.85e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—melanoma	6.82e-06	4.85e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MDM2—melanoma	6.8e-06	4.83e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CTNNB1—melanoma	6.79e-06	4.82e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—melanoma	6.77e-06	4.81e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—melanoma	6.76e-06	4.8e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CTNNB1—melanoma	6.76e-06	4.8e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1B1—melanoma	6.74e-06	4.79e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—melanoma	6.71e-06	4.77e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—melanoma	6.7e-06	4.76e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—melanoma	6.7e-06	4.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	6.69e-06	4.75e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—melanoma	6.67e-06	4.73e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MDM2—melanoma	6.66e-06	4.73e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—melanoma	6.66e-06	4.73e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1A—melanoma	6.63e-06	4.71e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—melanoma	6.62e-06	4.7e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—melanoma	6.62e-06	4.7e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CB—melanoma	6.62e-06	4.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGF2—melanoma	6.61e-06	4.7e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1A—melanoma	6.6e-06	4.69e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CB—melanoma	6.6e-06	4.69e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NFKB1—melanoma	6.59e-06	4.68e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—melanoma	6.58e-06	4.68e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—melanoma	6.57e-06	4.66e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NFKB1—melanoma	6.55e-06	4.65e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—melanoma	6.54e-06	4.64e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—melanoma	6.53e-06	4.64e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CG—melanoma	6.5e-06	4.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CB—melanoma	6.48e-06	4.6e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CTNNB1—melanoma	6.47e-06	4.59e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—melanoma	6.46e-06	4.59e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—melanoma	6.42e-06	4.56e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—melanoma	6.36e-06	4.52e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—melanoma	6.34e-06	4.5e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRAS—melanoma	6.32e-06	4.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1A—melanoma	6.32e-06	4.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—melanoma	6.3e-06	4.48e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NFKB1—melanoma	6.27e-06	4.46e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—melanoma	6.27e-06	4.45e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—melanoma	6.23e-06	4.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—melanoma	6.22e-06	4.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	6.21e-06	4.41e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1B—melanoma	6.21e-06	4.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MDM2—melanoma	6.19e-06	4.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRAS—melanoma	6.19e-06	4.39e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—melanoma	6.15e-06	4.37e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—melanoma	6.14e-06	4.36e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CG—melanoma	6.12e-06	4.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—melanoma	6.1e-06	4.33e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—melanoma	6.09e-06	4.32e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1B—melanoma	6.08e-06	4.32e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—melanoma	6.08e-06	4.32e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—melanoma	6.05e-06	4.29e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CB—melanoma	6.02e-06	4.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—melanoma	6.01e-06	4.27e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—melanoma	5.98e-06	4.25e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—melanoma	5.96e-06	4.23e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—melanoma	5.95e-06	4.23e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—melanoma	5.95e-06	4.22e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—melanoma	5.92e-06	4.21e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—melanoma	5.92e-06	4.21e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—melanoma	5.92e-06	4.2e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—melanoma	5.91e-06	4.2e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NRAS—melanoma	5.9e-06	4.19e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—melanoma	5.89e-06	4.18e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NRAS—melanoma	5.87e-06	4.17e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CTNNB1—melanoma	5.87e-06	4.17e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—melanoma	5.8e-06	4.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—melanoma	5.78e-06	4.11e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—melanoma	5.75e-06	4.09e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRAS—melanoma	5.75e-06	4.08e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CTNNB1—melanoma	5.74e-06	4.08e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1A—melanoma	5.73e-06	4.07e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—melanoma	5.72e-06	4.06e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CD—melanoma	5.71e-06	4.06e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—melanoma	5.7e-06	4.05e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—melanoma	5.69e-06	4.04e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NFKB1—melanoma	5.69e-06	4.04e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK3—melanoma	5.65e-06	4.02e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1B—melanoma	5.65e-06	4.01e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—melanoma	5.64e-06	4.01e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—melanoma	5.64e-06	4e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—melanoma	5.63e-06	4e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK3—melanoma	5.63e-06	4e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NRAS—melanoma	5.62e-06	3.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1A—melanoma	5.61e-06	3.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—melanoma	5.6e-06	3.98e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—melanoma	5.59e-06	3.97e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—melanoma	5.58e-06	3.96e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NFKB1—melanoma	5.57e-06	3.96e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—melanoma	5.56e-06	3.95e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCB1—melanoma	5.55e-06	3.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—melanoma	5.54e-06	3.93e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—melanoma	5.53e-06	3.93e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—melanoma	5.5e-06	3.91e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—melanoma	5.5e-06	3.91e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—melanoma	5.47e-06	3.89e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—melanoma	5.46e-06	3.88e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—melanoma	5.39e-06	3.83e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK3—melanoma	5.39e-06	3.83e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CD—melanoma	5.38e-06	3.82e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK1—melanoma	5.38e-06	3.82e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—melanoma	5.38e-06	3.82e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK1—melanoma	5.35e-06	3.8e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—melanoma	5.35e-06	3.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CTNNB1—melanoma	5.34e-06	3.79e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—melanoma	5.31e-06	3.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—melanoma	5.24e-06	3.72e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—melanoma	5.23e-06	3.72e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1A—melanoma	5.21e-06	3.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—melanoma	5.2e-06	3.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NFKB1—melanoma	5.18e-06	3.68e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—melanoma	5.16e-06	3.67e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK1—melanoma	5.12e-06	3.64e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—melanoma	5.12e-06	3.64e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—melanoma	5.11e-06	3.63e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PRKCA—melanoma	5.11e-06	3.63e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NRAS—melanoma	5.1e-06	3.62e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—melanoma	5.08e-06	3.61e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—melanoma	5.07e-06	3.6e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ERCC2—melanoma	5.07e-06	3.6e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—melanoma	5.06e-06	3.59e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—melanoma	5.06e-06	3.59e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—melanoma	5.01e-06	3.56e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NRAS—melanoma	4.99e-06	3.55e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CB—melanoma	4.98e-06	3.54e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—melanoma	4.93e-06	3.5e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK3—melanoma	4.89e-06	3.47e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—melanoma	4.84e-06	3.44e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK3—melanoma	4.78e-06	3.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—melanoma	4.75e-06	3.38e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—melanoma	4.7e-06	3.34e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CB—melanoma	4.69e-06	3.33e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—melanoma	4.67e-06	3.32e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—melanoma	4.65e-06	3.3e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—melanoma	4.65e-06	3.3e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK1—melanoma	4.65e-06	3.3e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—melanoma	4.65e-06	3.3e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—melanoma	4.65e-06	3.3e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—melanoma	4.64e-06	3.3e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NRAS—melanoma	4.64e-06	3.3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK1—melanoma	4.55e-06	3.23e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—melanoma	4.55e-06	3.23e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—melanoma	4.54e-06	3.23e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—melanoma	4.52e-06	3.21e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—melanoma	4.49e-06	3.19e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—melanoma	4.45e-06	3.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK3—melanoma	4.44e-06	3.16e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—melanoma	4.39e-06	3.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—melanoma	4.39e-06	3.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—melanoma	4.32e-06	3.07e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRAS—melanoma	4.32e-06	3.07e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—melanoma	4.3e-06	3.06e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—melanoma	4.3e-06	3.06e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—melanoma	4.3e-06	3.05e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRAS—melanoma	4.3e-06	3.05e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK1—melanoma	4.23e-06	3e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—melanoma	4.23e-06	3e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—melanoma	4.13e-06	2.94e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRAS—melanoma	4.11e-06	2.92e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—melanoma	4.11e-06	2.92e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—melanoma	4.05e-06	2.88e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—melanoma	4.03e-06	2.87e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—melanoma	4.02e-06	2.86e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CG—melanoma	4e-06	2.84e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—melanoma	3.99e-06	2.84e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—melanoma	3.95e-06	2.81e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—melanoma	3.94e-06	2.8e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—melanoma	3.9e-06	2.77e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—melanoma	3.86e-06	2.74e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—melanoma	3.82e-06	2.71e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—melanoma	3.81e-06	2.71e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—melanoma	3.79e-06	2.7e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRAS—melanoma	3.73e-06	2.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—melanoma	3.67e-06	2.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRAS—melanoma	3.65e-06	2.6e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—melanoma	3.63e-06	2.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—melanoma	3.59e-06	2.55e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—melanoma	3.57e-06	2.54e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—melanoma	3.55e-06	2.52e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CD—melanoma	3.52e-06	2.5e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—melanoma	3.5e-06	2.48e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—melanoma	3.47e-06	2.47e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRAS—melanoma	3.4e-06	2.41e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—melanoma	3.3e-06	2.34e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—melanoma	3.29e-06	2.33e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—melanoma	3.25e-06	2.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—melanoma	3.23e-06	2.29e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CB—melanoma	3.07e-06	2.18e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—melanoma	3.04e-06	2.16e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—melanoma	3.03e-06	2.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—melanoma	3e-06	2.13e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—melanoma	2.86e-06	2.03e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—melanoma	2.65e-06	1.88e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—melanoma	2.48e-06	1.76e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—melanoma	2.34e-06	1.66e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—melanoma	1.87e-06	1.33e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—melanoma	1.53e-06	1.08e-05	CbGpPWpGaD
